1. Eye movement desensitization and reprocessing for depressed individuals with multiple sclerosis: A pilot study.
- Author
-
Rovaris M, Toselli E, Mendozzi L, Di Tella S, Pirastru A, Blasi V, Baglio F, Ostacoli L, D'Abramo A, Incerti A, Fernandez I, Pagnini F, and Cavalera C
- Subjects
- Humans, Pilot Projects, Female, Male, Adult, Middle Aged, Magnetic Resonance Imaging, Treatment Outcome, Depressive Disorder therapy, Eye Movement Desensitization Reprocessing methods, Multiple Sclerosis therapy, Multiple Sclerosis complications, Multiple Sclerosis physiopathology, Depression therapy, Depression etiology
- Abstract
Background: Multiple studies have highlighted elevated rates of depression among individuals with Multiple Sclerosis (MS), with its associated symptoms posing a significant threat to overall well-being. Moreover, existing literature suggests a potential interconnection between depressive manifestations and the decline of physical functionalities in the context of MS., Objective: to examine the viability of the Eye Movement Desensitization Reprocessing (EMDR) therapy protocol for the treatment of depressive disorders (DeprEND) for alleviating depression in individuals with MS., Methods: We conducted a process-outcome study to examine the feasibilty and effectiveness DeprEND enrolling 13 individuals with MS and depressive symtpoms. Psychological and physical assessment pre-, post-intervention and 3-month follow-up were included. Pre- and post-magnetic resonance imaging (MRI) scans were conducted to analyze potential alterations in brain function., Results: The EMDR DeprEND treatment showed a high level of adherence and feasibility. Significant reductions in depressive symptoms were found at post-intervention and at 3 months follow-up. No significant differences were observed in terms of physical symptoms. A significant modulation observed in parietal and premotor areas when examining negative valence stimuli post-treatment was found., Conclusion: for The EMDR DeprEND protocol may represent a feasible and cost-effective treatment for reducing depressive symptoms in MS patients and improving their mental well-being., Competing Interests: Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
- Published
- 2024
- Full Text
- View/download PDF